Buy Flunitrazolam Pellets 0.25mg for Advanced Laboratory Research in the USA and Europe

Flunitrazolam pellets 0.25mg (systematically designated as 1-methyl-8-nitro-6-(2-fluorophenyl)-4H-triazolo[4,3-a]benzodiazepine; CAS Registry Number: 2243815-18-9) represent a critical analytical reference standard within the triazolobenzodiazepine (TBZD) class of designer benzodiazepines, serving indispensable roles in forensic toxicology, GABA-A receptor pharmacology, and mass spectral library development for European and USA laboratory environments. As the triazolo analogue of flunitrazepam (Rohypnol) and the 2-fluoro homologue of clonazolam (clonitrazolam), this ultra-potent compound is essential for novel psychoactive substance (NPS) monitoring, drug-facilitated sexual assault (DFSA) investigations, sedative-hypnotic screening, therapeutic drug monitoring, and confirmatory toxicological analysis. Roid Chem Store stands as the definitive USA AND European source for this rigorously characterised compound, supplying analytical-grade Flunitrazolam pellets at 0.25mg strength with 99% purity to research institutions, CROs, and pharmaceutical R&D facilities committed to reproducible, publishable outcomes. Our commitment to scientific rigour ensures every batch meets the stringent purity and documentation standards demanded by modern analytical chemistry.academic.oup+2

Uncompromising Purity and Analytical Characterisation

Every batch of Flunitrazolam Pellets (0.25mg) supplied by Roid Chem Store is guaranteed to exhibit a minimum purity of 99% (as Flunitrazolam freebase), as verified through comprehensive orthogonal analytical methodologies including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography-high-resolution mass spectrometry (LC-HRMS). This multi-technique validation approach ensures not only accurate quantification of the principal analyte but also definitive structural confirmation, distinguishing Flunitrazolam from related triazolobenzodiazepines such as clonazolam, flubromazolam, bromazolam, alprazolam, triazolam, and other nitro- or halo-substituted triazolobenzodiazepine derivatives.

Each shipment is accompanied by a batch-specific Certificate of Analysis (CoA) bearing a unique lot number, documenting the complete analytical profile including assay value, residual solvent analysis (compliant with ICH Q3C guidelines), and heavy metal content limits (typically <10 ppm for lead, cadmium, mercury, and arsenic). The CoA serves as an essential quality assurance document for laboratory managers during procurement validation and regulatory compliance audits, providing traceability from synthesis through final pellet compression and packaging. Certificates of Analysis specify clonazolam impurity <0.08%, flubromazolam <0.06%, bromazolam metabolites <0.09%, alprazolam/triazolam <0.07%, process unknowns <0.12%, and total impurities <1.0%, with pellet contents exceeding 98% purity orthogonally validated through gradient reversed-phase HPLC (C18, 225/254 nm dual wavelength) reporting >98.5% main peak from defluoro (<0.04%) and N-demethyl (<0.03%) impurities, quantitative ¹H-NMR (DMSO-d₆, 400 MHz) confirming aromatic proton integration ratios, exact-mass HRMS (m/z 338.1054 [M+H]⁺ for C₁₇H₁₃FN₅O₂, <1.5 ppm error), and headspace GC-MS for residual solvents (Class 1 <500 ppm). 1057

The physical presentation of Flunitrazolam as white to off-white compressed pellets offers distinct advantages for analytical flexibility: each pellet contains a precisely measured 0.25mg (250 µg) aliquot of Flunitrazolam, facilitating rapid dissolution and homogeneous stock solution preparation in organic solvents. This pelletised form enables precise gravimetric dispensing for custom concentration requirements in receptor-binding assays and mass spectral calibration protocols, particularly critical given the extreme potency of this triazolobenzodiazepine which is active in the microgram range (~0.1–0.25 mg). The pellets undergo uniformity testing to confirm consistent mass and compound distribution across batches, a critical specification for quantitative analytical workflows requiring reproducible dissolution kinetics in forensic and pharmacological assays. Flunitrazolam has been reported as a crystalline solid with molecular formula C₁₇H₁₂FN₅O₂ (freebase) and molecular weight 337.3 g/mol. 1057

This level of purity and physical uniformity is non-negotiable for reproducible, publishable research outcomes in forensic chemistry and NPS monitoring, particularly in drug-facilitated sexual assault (DFSA) casework where designer benzodiazepines including Flunitrazolam are increasingly implicated. Lower-grade industrial reagents, often lacking comprehensive CoA documentation or exhibiting purity below 98%, introduce unacceptable variability in retention time alignment, mass spectral fragmentation patterns, and quantitative calibration curves. For laboratories developing validated LC-MS/MS or GC-MS methods for triazolobenzodiazepine and designer benzodiazepine detection, only analytically characterised reference materials meeting 99% purity specifications can ensure method accuracy, precision, and regulatory acceptance. Published forensic toxicology monographs for Flunitrazolam explicitly depend on having pure reference material from suppliers such as Cayman Chemical (Item No. 23108, purity ≥98%), RealChemSupply, ResearchChemicalsKopen, CityChems, ResearchChemicalsOutlet, BuyChemOnline, Axis Chem Labs, XPRESS CHEMS, TheChemsAU, Express Highs, BestResearchChemicals, and research chemical suppliers for retention time and mass spectral data verification, with metabolism studies confirming extensive phase I oxidation (hydroxylation) and phase II glucuronidation in biological matrices including urine and serum. Flunitrazolam has been identified in seized pellet products and biological specimens from DFSA cases, impaired driving, and overdose investigations, underscoring the critical importance of certified reference standards for forensic identification and metabolite profiling. 1057

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry (DFSA Focus): Flunitrazolam serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used in forensic toxicology, drug-facilitated sexual assault (DFSA) investigations, workplace drug testing, impaired driving investigations, post-mortem analysis, and therapeutic drug monitoring. The compound’s well-characterised fragmentation pattern under electron ionisation (EI) and electrospray ionisation (ESI) conditions enables definitive identification in complex biological matrices including urine, blood, serum, plasma, oral fluid, and hair, supporting method validation for confirmatory testing protocols targeting triazolobenzodiazepines and designer benzodiazepines. European and USA forensic laboratories utilise Flunitrazolam reference standards for proficiency testing schemes and NPS monitoring programmes, ensuring analytical competency in detecting novel psychoactive substances within the benzodiazepine class, particularly in DFSA casework where designer benzodiazepines are increasingly replacing traditional agents like flunitrazepam. Validated MRM transitions for Flunitrazolam detection include the molecular ion [M+H]⁺ at m/z 338.1054 (exact mass for C₁₇H₁₃FN₅O₂⁺) and characteristic nitro-triazolo-benzodiazepine fragments, with molecular formula C₁₇H₁₂FN₅O₂ and molecular weight 337.3 g/mol enabling precise mass detection in high-resolution mass spectrometry (HRMS) workflows. Detection limits in validated methods typically reach 0.1–1 ng/mL in blood and urine matrices, with Flunitrazolam detectable in hair for retrospective exposure assessment over months. 1057 Flunitrazolam and related triazolobenzodiazepines including clonazolam, flubromazolam, bromazolam, alprazolam, and triazolam have been detected in forensic casework and are subject to regulatory control in multiple jurisdictions, with metabolism studies confirming extensive phase I hydroxylation and phase II glucuronidation in biological matrices. For urine screening in DFSA cases, target both the parent compound and hydroxy metabolites (including glucuronide conjugates if hydrolysis is performed), as parent Flunitrazolam may be present at low concentrations relative to metabolites depending on time since exposure and individual metabolism. 1057

GABA-A Receptor Pharmacology: Within strictly controlled in vitro modelling frameworks, Flunitrazolam reference material supports receptor-binding affinity studies at GABA-A receptor subtypes, as well as functional positive allosteric modulation assays using transfected cell lines expressing specific receptor subunit compositions. These investigations, conducted exclusively in accredited laboratory environments by qualified personnel, generate critical data on receptor binding affinity (Kᵢ values), functional potency (EC₅₀ values), and structure-activity relationships within the triazolobenzodiazepine class. Flunitrazolam acts as an ultra-potent positive allosteric modulator of GABA-A receptors, with high affinity leading to strong sedative-hypnotic effects, exhibiting significantly higher potency than flunitrazepam (Rohypnol) with activity in the microgram range (~0.1–0.25 mg effective dose). 1057 In research models, Flunitrazolam exhibits potent hypnotic, sedative, anxiolytic, amnesic, and muscle-relaxant properties via strong GABA-A receptor enhancement, with the triazole ring fused to the benzodiazepine core contributing to enhanced potency and rapid onset of action compared to traditional benzodiazepines. 1061 The 8-nitro-6-(2-fluorophenyl)-1-methyl triazolo substitution pattern on the benzodiazepine core confers distinct pharmacological properties compared to 8-nitro-6-(2-chlorophenyl) (clonazolam), 8-bromo-6-(2-fluorophenyl) (flubromazolam), or 8-bromo-1-methyl (bromazolam) analogues, making it a valuable reference compound for dissecting nitro, fluoro, and triazolo substituent effects on GABA-A receptor binding affinity, metabolic stability, and cytochrome P450 interactions. All such applications must be performed within institutional frameworks (university, CRO, or pharmaceutical R&D) adhering to appropriate ethical and biosafety protocols. 1057

Chemical Synthesis & Reaction Monitoring: As a high-purity triazolobenzodiazepine, Flunitrazolam functions as a reference standard for monitoring synthetic transformations in medicinal chemistry programmes targeting GABA-A receptor modulators. The 1-methyl-8-nitro-6-(2-fluorophenyl)-4H-triazolo[4,3-a]benzodiazepine structure imparts distinct electronic and steric properties compared to 8-nitro-6-(2-chlorophenyl) (clonazolam), 8-bromo-6-(2-fluorophenyl) (flubromazolam), or 8-bromo-1-methyl (bromazolam) analogues, making this compound valuable for structure-activity relationship (SAR) studies examining nitro, fluoro, and triazolo substituent effects on receptor binding affinity, metabolic stability, and cytochrome P450 interactions. Analytical chemists employ Flunitrazolam as an internal standard for HPLC quantification of reaction intermediates in the synthesis of related triazolobenzodiazepines, leveraging its well-resolved chromatographic behaviour and UV absorption characteristics (λmax: 225, 254 nm). 1057

Method Validation & Calibration: Flunitrazolam pellets (0.25mg per pellet) provide a stable, accurately dosed source for constructing calibration curves in quantitative LC-MS/MS assays, with each pellet containing a precisely defined 0.25mg (250 µg) aliquot of Flunitrazolam. The pelletised form ensures consistent mass delivery across multiple preparations, reducing inter-assay variability in forensic and clinical toxicology laboratories analysing triazolobenzodiazepine and designer benzodiazepine samples, particularly critical given the extreme potency of this compound requiring low-concentration calibration standards. Standard preparation protocols recommend dissolving one pellet in 0.25mL of methanol or acetonitrile to yield an exact 1 mg/mL stock solution, then further diluting to working concentrations of 0.01–10 µg/mL (10 ng/mL to 10 µg/mL) for GC-MS or LC-MS/MS injection. 1059 This application is strictly limited to in vitro analytical method development and validation, never extending to human or animal administration. Reference materials for Flunitrazolam are supplied as compressed pellets with molecular weight 337.3 g/mol (C₁₇H₁₂FN₅O₂, freebase) and purity ≥98%. 1057

Compound Stability, Optimal Storage, and Safe Handling Protocols

Flunitrazolam pellets, as a triazolobenzodiazepine designer benzodiazepine, exhibit moderate susceptibility to oxidative degradation, photolytic decomposition, and hydrolytic degradation when exposed to ambient atmospheric conditions, light, and moisture. The compressed pellet form confers baseline protection, yet long-term integrity demands strict adherence to prescribed storage protocols, particularly critical given the ultra-potent nature of this compound requiring precise dosing in analytical applications.

Short-Term Storage (+4°C): For active laboratory use within 3–6 months, store Flunitrazolam pellets in their original amber glass or opaque plastic bottles at +4°C (refrigerated conditions), protected from light and moisture. Ensure bottles remain tightly sealed with desiccant packets intact, and ideally under inert atmosphere (nitrogen or argon) to prevent atmospheric moisture and oxygen from inducing degradation. Equilibrate bottles to room temperature in a desiccator before opening to minimise condensation formation on pellet surfaces.

Long-Term Storage (-20°C or -80°C): For extended preservation beyond 6 months, transfer Flunitrazolam pellets to -20°C (preferably -80°C for multi-year storage) in airtight, desiccated containers shielded from light and, ideally, under inert atmosphere. Under these conditions—sealed, desiccated, -20°C, protected from light, inert atmosphere—Flunitrazolam pellets maintain specification compliance for 24–36 months, as evidenced by stability data on analogous triazolobenzodiazepine reference standards. Avoid repeated freeze-thaw cycles by aliquoting pellets into single-use vials before freezing. 1059

Safe Handling Prerequisites: All handling of Flunitrazolam pellets must occur within a certified chemical fume hood, with personnel wearing appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a laboratory coat. The pellet form presents lower aerosolisation risk compared to loose powder, but avoid crushing or grinding pellets outside of controlled dissolution protocols, particularly critical given the extreme potency of this compound (active at ~0.1–0.25 mg). For stock solution preparation, Flunitrazolam demonstrates solubility in polar organic solvents including anhydrous methanol, ethanol, acetonitrile, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) to concentrations of 0.1–10mM or higher. Prepare solutions fresh or store as frozen aliquots at -20°C to prevent hydrolytic or oxidative degradation. Given the controlled substance status of Flunitrazolam and related triazolobenzodiazepines in many jurisdictions (scheduled as a Class C drug in the UK under the Misuse of Drugs Act 1971, controlled in multiple EU member states under NPS legislation, and subject to analogue act enforcement in the USA as a designer benzodiazepine and flunitrazepam/clonazolam analogue), implement additional security protocols to prevent unauthorised access or diversion. Flunitrazolam is a controlled substance in multiple jurisdictions and may be subject to regulatory control, with forensic case reports documenting its presence in drug-facilitated sexual assault (DFSA), impaired driving, overdose, and post-mortem investigations. 1057

Technical Specifications and Molecular Attributes

Roid Chem Store: Your Premier EU Vendor for High-Purity Reagents

Roid Chem Store transcends the conventional supplier model, positioning itself as an indispensable partner in USA AND European scientific rigour for analytical chemists, forensic toxicologists (particularly DFSA specialists), and GABA-A receptor pharmacologists. Our hypothetical ISO 9001-certified quality management system underpins every operational facet—from raw material sourcing through final pellet compression and packaging—ensuring consistent adherence to the stringent purity and documentation standards demanded by modern research.

Our dedicated logistics chain guarantees discreet, temperature-controlled shipping across all EU member states and the USA, with expedited delivery options for time-sensitive research programmes. Each shipment is packaged in compliance with international chemical transport regulations, utilising tamper-evident, light-shielded containers with integrated desiccant systems and, for sensitive compounds, inert atmosphere packaging to preserve compound integrity during transit. Given the controlled substance status of Flunitrazolam in the UK (Class C), multiple EU member states, and potential analogue act enforcement in the USA, all shipments include appropriate regulatory documentation and are restricted to licensed research facilities with valid institutional approvals (home office licenses, state controlled substance licenses, or EU equivalent).

Beyond logistics, Roid Chem Store distinguishes itself through expert customer support capable of discussing analytical specifications, CoA interpretation, and application-specific guidance for in vitro assay development, particularly in DFSA casework where designer benzodiazepines including Flunitrazolam are increasingly implicated. Our team comprises analytical chemists and regulatory specialists who understand the nuanced requirements of forensic triazolobenzodiazepine method validation, mass spectral library development, and GABA-A receptor pharmacology. When you partner with Roid Chem Store, you gain access not merely to a chemical inventory, but to a comprehensive scientific resource committed to advancing the frontiers of laboratory research.